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The stromal cell antigen CD248 (endosialin) is expressed on naive
CD8+ human T cells and regulates proliferation
Introduction
CD248 is a 175 000 molecular weight type I transmem-
brane glycoprotein encoded on human chromosome
11q13.1 It is a member of a family of proteins that
includes CD93 and CD141 (thrombomodulin).2,3 CD248
was first characterized as a novel marker expressed on
tumour, but not normal, vascular endothelial cells.1 Also
known as ‘Tumour Endothelium Marker-1’,4–6 CD248 is
expressed on stromal cells in samples of breast carci-
noma,7 colon cancer,8 glioblastoma multiforme9 and
xenografts of colon carcinoma.5
More recently, CD248 has been shown to be expressed
on perivascular NG2+ cells in the tumour vasculature as
well as on interstitial fibroblasts and mesenchymal stem
cells rather than on endothelial cells per se.5,7,9–12 Of note,
CD248 expression on these stromal cells is developmen-
tally regulated, being high in embryonic and fetal tis-
sue5,10,11,13–15 but lost or substantially reduced in the
adult, with the exception of uterine tissue.15
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Summary
CD248 (endosialin) is a transmembrane glycoprotein that is dynamically
expressed on pericytes and fibroblasts during tissue development, tumour
neovascularization and inflammation. Its role in tissue remodelling is
associated with increased stromal cell proliferation and migration. We
show that CD248 is also uniquely expressed by human, but not mouse
(C57BL/6), CD8+ naive T cells. CD248 is found only on CD8+ CCR7+
CD11alow naive T cells and on CD8 single-positive T cells in the thymus.
Transfection of the CD248 negative T-cell line MOLT-4 with CD248
cDNA surprisingly reduced cell proliferation. Knock-down of CD248 on
naive CD8 T cells increased cell proliferation. These data demonstrate
opposing functions for CD248 on haematopoietic (CD8+) versus stromal
cells and suggests that CD248 helps to maintain naive CD8+ human T
cells in a quiescent state.
Keywords: angiogenesis; CD248/endosialin; CD8; naive T cells; tumour
therapy
Abbreviations: Cy, cyanine; mAb, monoclonal antibody; PE, phycoerythrin.
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Lack of CD248 expression correlates with a site-specific
reduction in the aggressiveness of xenograft tumours; a
finding that appears to be related to defects in the size of
tumour-associated neo-vessels.16 Given these findings and
the lack of any reported haematopoietic defects in the
CD248 knockout mouse,16 CD248 has been accepted as a
stromal-cell-specific marker.12 However, during an unbi-
ased screening for genes uniquely expressed in different
human blood cell subsets we discovered that CD248 was
one of only five specific transcripts that distinguished
CD8 T cells from other differentiated blood cells.17 Here
we characterize CD248 expression on human and mouse
haematopoietic cells. We show that CD248 expression on
leucocytes is confined to naive human, but not mouse,
CD8+ thymocytes and peripheral T cells. We have found
that CD248 unexpectedly inhibits T-cell proliferation,
suggesting that CD248 has opposing roles on CD8+ T
cells compared with stromal cells.
Materials and methods
Patient samples
Samples were taken with informed consent and local
research ethics committee approval (Birmingham: REC
2002/088, LREC 5735, 06/Q2706/66; Oxford: C01.097).
Tissue samples were collected immediately after surgical
removal and 5-lm acetone-fixed cryosections were used
for immunofluorescence. Suspensions of tonsil cells were
prepared by mechanical dispersion. Tonsil and blood leu-
cocytes were prepared by centrifugation (300 g for
25 min at room temperature) on a Ficoll–Paque Plus (GE
Healthcare, Little Chalfont, UK 17-1440-03). Neutrophils
were isolated from blood: after sedimentation for 35 min
with Dextran (Dextran to blood ratio of 1 : 7), they were
layered onto a 56%/80% Percoll (Sigma, Poole, UK
P4937) gradient, centrifuged at 200 g for 20 min and
neutrophils were harvested from the interface. Thymo-
cytes were prepared as described previously18 from chil-
dren undergoing heart surgery.
Immunofluorescence microscopy
Human tonsil, spleen and thymus tissues were labelled
with CD248 monoclonal antibodies (mAb) B1/35.1 (IgG1
supernatant7) in combination with: UCHT1 (IgG2b
17 lg/ml gift from Professor Peter Beverley, University of
Oxford, UK); OKT8 (IgG2a) and OKT4 (IgG2b; Ameri-
can Type Culture Collection, Manassas, VA) both 1 : 100
mouse ascitic fluid. Primary antibodies were detected with
goat antibodies against mouse IgG1-FITC (1070-02,
20 lg/ml), IgG2a-tetramethyl-rhodamine (1080-03, 20 lg/
ml) and IgG2b-Cyanine (Cy) 5 (1090-15, 4 lg/ml)
(SouthernBiotech, Birmingham, AL) in combination with
goat anti-FITC Alexa-488 (Invitrogen, Paisley, UK A-
11096, 10 lg/ml). All experiments using murine tissue
were performed in accordance with UK laws with
approval of local ethics committees. C57BL/6 mouse
spleen tissue was prepared as described previously13 and
stained with rabbit anti-CD248 P1310 (10 lg/ml) followed
by anti-rabbit Cy5 (Jackson ImmunoResearch, Newmar-
ket, UK 711-176-152, 15 lg/ml) and anti-CD3-FITC
(eBiosciences, Hatfield, UK 11-0031 antibody 145-2C11,
5 lg/ml) followed by anti-Armenian hamster Cy2 (Jack-
son ImmunoResearch 127-225-160, 14 lg/ml). Sections
were mounted in 24% 1,4-diazabicyclo[2,2,2]octane
(Sigma) in glycerol (Fisons Scientific, Loughborough,
UK) pH 86. With reference to controls, images were cap-
tured using a LSM 510 confocal microscope (Zeiss, Wel-
wyn Garden City, UK). Cytospins of transfected MOLT-4
cells were stained for CD248 as described above; in addi-
tion, nuclei were stained with 20 lg/ml Hoechst 33258
(bis-benzimid H33258 Fluorochrom; Riedel De Haen AG,
Buchs, Switzerland).
Flow cytometry and cell sorting
Primary and small interfering (si) RNA-treated cells were
stained using purified CD248 mAb B1/35.1 conjugated to
FITC (20 lg/ml) alone or in combination with CD3-
allophycocyanin-H7 (641397) and/or CD19-peridinin
chlorophyll protein (345790), CD56-phycoerythrin (PE)
(345810), CD14-PE (345785), CD16-PE-Cy7 (335823),
CD4-Pacific Blue (558116), CD45RA-PE (555489), CD11a-
allophycocyanin (559875), CCR7-PE-Cy7 (557648) (Becton
Dickinson Biosciences, Oxford, UK), CD8-Pacific Orange
(MHCD0830) (Invitrogen, Paisley, UK) and isotype con-
trols. For validation of CD248 expression by in vitro
models, transfectants were stained with unconjugated
CD248 mAb B1/35.1 detected with goat anti-mouse IgG-
FITC (SouthernBiotech 1010-02, 20 lg/ml). All samples
were assessed on a Cyan ADP flow cytometer (Beckman
Coulter, High Wycombe, UK) and data were analysed
using FLOWJO software v8.3 (Tree Star, Ashland, OR). To
analyse protein expression by Western blotting CD3+
blood leucocytes were labelled and sorted for CD4 and
CD45RA, CD4 and CD45RO, CD8 and CD45RO or CD8
and CD45RA populations. Populations were sorted to
> 99% purity using a MoFlow cell sorter (Beckman
Coulter).
Western blot
T-cell subsets isolated as described above, rheumatoid
arthritis synovial fibroblasts and human umbilical vein
endothelial cells isolated as previously described,19 were
lysed in non-reducing buffer and run on a 10% polyacryl-
amide gel. Gel bands were transferred to a 045 lm PVDF
membrane (Flowgen Limited, Nottingham, UK) and
blocked with 5% non-fat dried milk in Tris-buffered saline
 2011 The Authors. Immunology  2011 Blackwell Publishing Ltd, Immunology, 133, 288–295 289
CD248 on naive CD8 T cells
and stained with CD248 mAb B1/35.1 supernatant (1 : 10)
or b-actin (1/1000) and detected with human immuno-
globulin-absorbed goat anti-mouse immunoglobulin con-
jugated to horseradish peroxidase (GE Healthcare). The
blot was visualized by enhanced chemiluminescence (GE
Healthcare) and autoradiography (Kodak X-OMAT,
Watford, UK).
Transfected T-cell lines
MOLT-4 T cells (American Type Culture Collection CRL-
1582) were transfected with pcDNA3.1 or pcDNA3.1-
huCD2487 using electroporation (Lonza, Slough, UK
L-VCA-1005). CD248+ cells were selected by culture in
500 lg/ml Geneticin (Invitrogen 10131019) and by
positive selection using magnetic beads coated with
anti-mouse IgG (DynaM-450 beads, Invitrogen 110.41) to
detect cells labelled with B1/35.1.7
Thymidine incorporation assay
Uptake of [3H]thymidine was used as an indication of
the relative spontaneous proliferative rates of pcDNA3.1-
and pcDNA3.1-CD248-transfected MOLT-4 cells. Cultures
of each transfectant were set up in triplicate in 96-well
flat-bottomed plates using 100 ll of cells at 0025 · 106,
005 · 106, 01 · 106, 02 · 106, 03 · 106, 04 · 106 and
08 · 106 cells/ml. On day 1 cells were pulsed for 6 hr
with 50 ll of 1 lCi/ml [3H]thymidine, harvested (Ska-
tron, Tranby, Norway, 7022 cell harvester) onto filter
mats (Perkin Elmer, Waltham, MA, GF-Filter 1205-401)
and the radioactivity was measured in counts/min using a
beta-counter (Perkin Elmer, Wallac 1205).
Naive CD8 T cells and CD248 siRNA
Naive CD8 T cells were isolated to 86% purity using a
CD8 T-cell isolation kit (Miltenyi Bergisch Gladbach,
Germany 130-094-156) followed by depletion of
CD45RO+ cells (Miltenyi 130-046-001) according to the
manufacturer’s instructions. Up to 10 · 106 cells were
transfected with 1 ll of 100 lM CD248 siRNA (Thermo
Scientific, Epsom, UK ON-TARGETplus SMARTpool
L-010720-01-005) or 1 ll of 1 lg/ll scrambled siRNA
(gift from Arthrogen, Amsterdam, The Netherlands) in
the presence of 100 ll human T-cell Nucleofector
solution (Lonza VPA-1002) using program U014
according to the manufacturer’s instructions (Amaxa
Biosystems). After 48 hr the relative level of CD248 was
compared by flow cytometry as above and by quantita-
tive PCR: CD248 and 18s expression was assayed using
a 7500 Taqman instrument (Applied Biosystems, Paisley,
UK, Taqman Gene Expression Assay Hs00535586_s1
and 18s rRNA 4319413E). Cells treated with CD248siR-
NA and scrambled siRNA were incubated for 24 hr at
+ 37 (in Dulbecco’s Modified Eagle’s Medium, Gibco,
Figure 1. CD248 is expressed on human stro-
mal cells and cells with lymphoid morphology.
Examples of CD248+ lymphoid cells that reside
in the extrafollicular area (EFA) but not the
germinal centre (GC) are circled. These are
CD3+ cells (a) that are CD4) CD8+ and were
present in tonsil (b), spleen (c) and thymus
(d). Boxes indicate areas shown at higher mag-
nification on the right. Data are representative
images from at least three different donors for
tonsil and spleen and one for thymus. Scale
bars represent 50 lm.
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Paisley, UK 41966; with 10% fetal calf serum, Biosera,
Ringmer, UK 51810-500) and the relative level of pro-
liferation was compared using 5-ethynyl-20-deoxyuridine
(EdU) incorporation.
EdU incorporation assay
Naive CD8 T cells were cultured for 3 days in Dulbecco’s
modified Eagle’s medium with 10% fetal calf serum at
05 · 106/ml in 250-ll aliquots with 2 lM EdU and 0,
125, 25 or 5 ll of T-cell expander Dynabeads (Invitro-
gen 111.31D). The level of EdU incorporation was mea-
sured using a Click-iT EdU Pacific Blue Flow
Cytometry Assay kit (Invitrogen A10034) according to the
manufacturer’s instructions. Samples were processed for
flow cytometry as previously stated.
Results
CD248 is expressed in human, but not murine, cells
with lymphoid morphology
To explore the distribution of CD248 on T cells we ini-
tially examined expression in the extrafollicular T-cell area
of human tonsils (Fig. 1a). CD248 co-localized with
CD3+ T cells (Fig. 1a) that were CD8+ but not CD4+
(Fig. 1b). Similar populations of cells were also found in
human spleen and thymus (Fig. 1c,d). As CD248 is
expressed on both human and mouse stromal cells, we
next examined whether CD248 was expressed on T cells
in murine lymphoid tissues. We were unable to identify
any CD3+ cells expressing CD248 in murine lymph node,
spleen and thymus (Fig. 2a–c), which is consistent with
previous reports that CD248 mRNA is absent from all
haematopoietic cell lineages in mice.20
CD248 expression on CD3+ T cells is restricted to
naive CD8+ T cells
To further investigate the expression of CD248 on human
blood leucocytes we screened a variety of leucocyte sub-
sets using a panel of CD248 antibodies that have been
characterized extensively.7,17 A distinct subset of CD3+ T
cells expressed CD248 (Fig. 3). CD248 was not identified
on any other leucocyte subsets including CD19+ B cells,
Figure 2. CD248+ T cells are not present in C57/BL6 mice. CD248+
(green) T cells (CD3+ red) were not present in lymph node (a),
spleen (b) or thymus (c) of mice. RP, red pulp; WP, white pulp.
Scale bars represent 50 lm. Boxes indicate areas shown at higher
magnification on the right. Data are representative images from at
least three different mice.
Figure 3. CD248 is expressed on a subset of CD3+ T cells from
human blood. Flow cytometry of CD248 antibody B1/35.1 in com-
parison with negative controls showing that CD248 is expressed on a
subset (85%) of CD3+ lymphocytes from blood. CD19+, CD56+,
CD14+ and CD16+ cells are CD248). B, T and natural killer cells are
forward scatter/side scatter (FSC/SSC) gated for lymphocytes, CD14+
cells are FSC/SSC gated for monocytes and CD16+ cells are FSC/SSC
gated for neutrophils. Data are representative plots from a minimum
of three experiments from different donors.
 2011 The Authors. Immunology  2011 Blackwell Publishing Ltd, Immunology, 133, 288–295 291
CD248 on naive CD8 T cells
CD56+ natural killer cells, CD14+ monocytes or CD16+
neutrophils (Fig. 3). CD248 expression on CD3+ T cells
was confined to CD8+ cells in both blood and tonsil
(Fig. 4a), which was consistent with our findings by
immunohistology (Fig. 1).
As human CD8 T cells can be divided into ‘naive’
(CD45RA+) and ‘primed’ (CD45RO+) subsets21 we next
investigated whether CD248 expression was confined to
one or other of these populations. CD248+ CD8+ T cells
were found exclusively in the CD45RA+ population in
both human blood and tonsil (Fig. 4a). Moreover CD248
was expressed on CCR7+ CD11alow cells, indicating that
CD248 is confined to naive CD8+ T cells (Fig. 4a) and
Figure 4. CD248 is expressed on naive CD8+ T cells and mature
human thymocytes. CD248 is expressed by a distinct subset of
CD8+ CD3+ T cells that is CD45RA+ CCR7+ CD11alow and is pres-
ent in blood and tonsil (a). Samples are gated in comparison with
isotype controls. Data are representative plots from a minimum of
five samples each. (b) Western blot (n = 1) showing CD248 protein
expression only in rheumatoid arthritis synovial fibroblasts and
CD8+ CD45RA+ T cells and not other T-cell subsets or HUVEC. (c)
CD248+ CD3+ thymocytes (n = 1) are only found in the single-
positive CD4) CD8+ population of T cells.
Figure 5. Human (hu) CD248 transfection of MOLT-4 T cells
resulted in decreased proliferation. CD248 monoclonal antibody B1/
35.1 staining of surface (a) and fixed (b) MOLT-4 T cells transfected
with either huCD248-pcDNA3.1 or pcDNA3.1 vector alone show
that only the CD248 transfected line has high expression of CD248.
Insets in (b) are nuclear counterstains. Scale bars represent 10 lm
(n  3). Comparison of the [3H]thymidine uptake of MOLT-4 T
cells transfected with CD248-pcDNA3.1 (•) or pcDNA3.1 vector
alone (s) shows that CD248+ cells have lower spontaneous prolifera-
tive capacity than their vector alone-transfected counterparts (c).
This was demonstrated across a range of cell numbers and on day 1
of culture (n = 7). *P < 005, **P < 001, ***P < 0001. The Stu-
dent’s paired t-test was applied to compare the statistical significance
of linked data. Error bars represent SEM.
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not to CCR7low/) CD11ahigh CD45RA+ effector (‘revert-
ant’) memory cells.22
To confirm protein expression of CD248 on CD8+/
CD45RA+ cells, CD4+ and CD8+ CD45RA+ and CD45RO+
cells were isolated to > 99% purity by FACS sorting, and
CD248 expression was examined by Western blot. Rheu-
matoid arthritis synovial fibroblasts and human umbilical
vein endothelial cells were used as positive and negative
controls, respectively.7 Only CD8+ CD45RA+ cells and fi-
broblasts expressed CD248 (175 000 molecular weight)
(Fig. 4b).
CD248 is not expressed until the CD8 single-positive
stage in T-cell develpoment in human thymus
We next explored at what stage during the development
of CD8+ T cells CD248 was expressed by studying human
thymocytes. At the earliest stage of development thymo-
cytes are double negative for CD4 and CD8. Following
re-arrangement of their T-cell receptor a and b chains,
they become double positive for CD4 and CD8, then
before positive and negative selection they become single
positive for CD4 or CD8.23 We observed that CD248
expression was restricted to the CD8+ CD4) population
of thymocytes (Fig. 4c), suggesting that expression occurs
during late thymocyte development when naive T cells
begin to leave the thymus and migrate to secondary lym-
phoid tissues via the blood and lymphatics.
CD248 inhibits T-cell proliferation
CD248 has been reported to induce cell proliferation on
stromal cells such as primary human and mouse embry-
onic fibroblasts,8,24 human (hu) CD248 transfected Chi-
nese hamster ovary cells25 and MG63 human
osteosarcoma cells.24 We therefore examined whether
CD248 could regulate T-cell proliferation using a CD248-
negative acute T-cell leukaemia cell line (MOLT-4) trans-
fected with huCD248-pcDNA3.17 or pcDNA3.1 vector
alone. High and stable levels of CD248 expression were
achieved by iterative rounds of selection (Fig. 5a,b).
CD248-transfected T cells had a significantly lower (mean
P < 0005) capacity for proliferation than their vector
alone-transfected counterparts (Fig. 5c). Interestingly, the
differences in proliferation between these two cell lines
were most pronounced at higher cell densities.
Figure 6. CD248 expression is associated with decreased prolifera-
tion of naive CD8 T cells. Quantitative PCR was used to demon-
strate significantly lower levels (**P < 001) of CD248 RNA
expression in CD248 small interfering (si) RNA-treated cells com-
pared with controls (n = 3) (a). Significantly reduced protein expres-
sion (*P < 005) of CD248 in CD248 siRNA-treated cells compared
with controls was also demonstrated (n = 3) (b). Cells were cultured
with 0, 125, 25 or 5 ll T-cell expander beads for 3 days then their
proliferation was compared using an 5-ethynyl-20-deoxyuridine
(EdU) incorporation assay. CD248 siRNA-treated naive CD8 T cells
( ) exhibit higher EdU incorporation than scrambled siRNA-
treated cells ( ). Data from three different donors are shown
in (c) and the data are grouped in (d) showing CD248 siRNA trea-
ted naive CD8 T cells ( ) exhibit significantly higher (*P < 005)
EdU incorporation than scrambled siRNA-treated cells ( ). The
Student’s paired t-test was applied to compare the statistical signifi-
cance of linked data. Error bars represent SEM.
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To confirm and extend our findings we knocked down
CD248 expression on freshly isolated human CD8 T cells
(Fig. 6a,b). CD248 expression on haematopoietic cells was
associated with reduced proliferation as CD248 siRNA
treatment of naive CD8 T cells significantly increased
(P < 005) their proliferative capacity (Fig. 6c,d).
Discussion
In this report we confirm that CD248 is expressed by
naive human CD8+ T cells and paradoxically inhibits T-
cell proliferation compared with stromal cells where it
increases proliferation. Differences in T-cell proliferation
were more pronounced at higher cell densities and may
reflect higher CD248 expression at these densities.14
CD248 is not expressed on lymphoid cells in adult mouse
spleen, thymus or lymph node, which is consistent with a
lack of mRNA expression in murine haematopoietic
cells20 as well as the lack of any T-cell phenotype in
CD248 knockout mice.16 The reason for this difference
between haematopoietic expression in human and mouse
lymphocytes warrants further exploration.
We found unexpected functional effects of CD248 on
human T cells that contrast strikingly with those reported
for stromal cells.8,24,25 Whereas CD248 enhances stromal
cell proliferation,8,24,25 we were surprised to find that
CD248 expression in human T cells inhibited prolifera-
tion. Contrasting effects of the same molecule expressed
on stromal versus haematopoietic cells have been reported
previously26,27 and serve to underline that there must be
differential ‘gearing’ of the signalling pathways for CD248
in these two cell types. A role for intracellular signalling
via the cytoplasmic domain of CD248 has been shown
using a stromal cell mouse model where absence of the
cytoplasmic domain resulted in reduced inflammation,
measured in part by decreased leucocyte adhesion to stro-
mal cells.28 Investigation of the function of intracellular
signalling domains in CD248 will contribute to an under-
standing of the differential effects of stromal and T-cell
CD248.
We found CD248 expression on naive CD8+ T cells in
the circulation and in the extrafollicular areas of secondary
lymphoid tissue (Fig. 1). The extrafollicular zone is an
important site of antigen presentation to naive T cells, typ-
ically followed by rapid division and effector/memory T-
cell generation.29 As this occurs concomitantly with declin-
ing expression of CD248 it is tempting to speculate that
CD248 might play a role in retaining naive T cells at sites
where they can encounter antigen. The loss of CD248
expression after exposure to antigen is associated with the
ability to divide rapidly and migrate to follicular sites. In
antigenic responses and in comparison to their memory
counterparts, naive CD8 T cells exhibit lower intrinsic pro-
liferative capacity.22 Our data indicate that CD248 might
play a role in these processes in CD8 T cells. Why CD248
is expressed only on CD8+ and not CD4+ naive T cells is
not clear but needs further investigation.
Reports on CD248 have, up to now, suggested that its
expression is restricted to stromal and mesenchymal
cells.12,30,31 Much interest has centred on its role(s) in the
angiogenic processes that occur during tumour progres-
sion and in tissue remodelling following inflammatory
stimuli. The data presented here point to unexpected
expression and opposing functional effects of CD248 on
naive human CD8+ T cells compared with stromal cells.
Our findings suggest that a careful analysis of the role of
CD248 on naive CD8 T cells in vivo is needed particularly
with regard to the use of anti-CD248 reagents in the
advocated and current treatment of solid tumours.9,32,33
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